Sopaan Pharmaceuticals IPO: Last Day to Apply for Public Shares in Nepal

Today marks the final opportunity for investors to apply for the Initial Public Offering (IPO) of Sopaan Pharmaceuticals Limited, which opened for the general public earlier this week.

The company began issuing its IPO on Baisakh 3 and has set Baisakh 8 as the last date for application under the public category.

IPO Structure and Share Allocation Details

Sopaan Pharmaceuticals Limited received approval to issue shares worth NPR 429 million, representing 25% of its total issued capital of NPR 1.716 billion. This translates to 4.29 million shares.

Before opening for the general public, the company had already allocated shares in different categories:

• 10% (429,000 shares) for Nepali citizens working abroad
• 171,600 shares for company employees
• 214,500 shares for mutual funds

After these allocations, the remaining 3,474,900 shares (worth NPR 347.49 million) are now available for the general public at a face value of NPR 100 per share.

Application Limits for Investors

Investors interested in this IPO must follow these application guidelines:

• Minimum application: 10 shares
• Maximum application: 11,000 shares

This provides flexibility for both small and large investors to participate in the offering.

How to Apply for Sopaan Pharmaceuticals IPO

The IPO is being managed by NMB Capital Limited. Investors can apply through:

• ASBA-approved banks and financial institutions
• Designated branch offices
• Online via the Mero Share system developed by CDS and Clearing Limited

Applications must be submitted through the C-ASBA system before the deadline.

Credit Rating and Investment Risk

For this IPO, CARE Ratings Nepal has assigned the company a CARE-NP Single B Issuer Rating.

This rating indicates a high level of risk in the company’s ability to meet its financial obligations, meaning investors should carefully evaluate before investing.

Financial Indicators and Returns

Key financial metrics for the company include:

• Payback Period: 8.11 years
• Discounted Payback Period: 11.35 years
• Net Present Value (NPV): NPR 15.97 billion
• Internal Rate of Return (IRR): 23.63%

These figures provide insight into the company’s long-term financial performance and potential returns.

Final Reminder for Investors

With today being the last day to apply, investors interested in the IPO of Sopaan Pharmaceuticals Limited should ensure they submit their applications before the deadline.